3 full days of unmissable content sessions covering key challenges from discovery through to the clinic

3 revitalized workshop sessions to take part in intimate discussions with myeloid-cell experts who have faced the same challenges as you 

14 industry specific case studies covering the evolving spectrum of myeloid-directed therapies to induce potent anti-tumor immune responses in solid and haem tumors 

Uncover the full range of existing and novel targets being discussed from CD40 to LILRB to STING, RORg and PI3-gamma